
Microcap Cognition Therapeutics (NASDAQ:CGTX) has skyrocketed 35% in Thursday trading after stating the company had a positive end-of-phase 2 meeting with the U.S. FDA for the oral Alzheimer's asset zervimesine and sees a path forward for a phase 3
Microcap Cognition Therapeutics (NASDAQ:CGTX) has skyrocketed 35% in Thursday trading after stating the company had a positive end-of-phase 2 meeting with the U.S. FDA for the oral Alzheimer's asset zervimesine and sees a path forward for a phase 3